A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Titration Proof of Concept Study in Patients With Huntington's Disease to Assess the Efficacy, Safety and Tolerability of AFQ056 in Reducing Chorea.

Trial Profile

A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Titration Proof of Concept Study in Patients With Huntington's Disease to Assess the Efficacy, Safety and Tolerability of AFQ056 in Reducing Chorea.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2015

At a glance

  • Drugs Mavoglurant (Primary)
  • Indications Huntington's disease
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 17 Feb 2015 Primary endpoint of Orientation index has not been met, according to results published in the Movement Disorders.
    • 30 Jul 2013 Primary endpoint 'Unified-Huntington's-Disease-Rating-Scale' has not been met.
    • 30 Jul 2013 Status changed from active, no longer recruiting to completed, based on presentation of results.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top